VEGFA and glioma: G47∆, armed with murine IL-12, showed improved efficacy in immunocompetent glioma-bearing mice through inducing IFN-γ production, downregulating proangiogenic vascular endothelial growth factor (VEGF), and ameliorating the immunosuppressive TME [100].